MorphoSys Unveils New Antibody Library, HuCAL PLATINUM(R)
MorphoSys AG has announced the successful completion of a new proprietary antibody library, HuCAL PLATINUM. Initial results show that the new antibody library, which is approximately three-times larger than the former version, HuCAL GOLD, can provide a more diverse range of fully human antibodies. In addition, the new technology enables the generation of antibodies having higher affinity as well as improved expression rates. The improvements achieved with this next generation antibody library are expected to significantly shorten timelines from antibody discovery to pre-clinical development and result in antibody drug candidates with improved characteristics.

Scientists from the University of Cambridge have found that alemtuzumab, a drug originally developed for leukemia can curb the progression of multiple sclerosis (MS) even reverse some damage caused by the neurological disorder. The drug, a monoclonal antibody, has also been tested for treatment of other immune system disorders. Alemtuzumab targets the cells of the immune system that attack the myelin sheath and the nerve fibers.
New data from an extended follow-up study show that 